£3m Investment in Coleraine Companies Will Improve Outcomes for Cancer and Metabolic Disease Patients

£3m investment in Coleraine companies will improve outcomes for cancer and metabolic disease patients

Invest Northern Ireland has announced that two Coleraine life and health science companies are the first to receive investment from its £39m equity fund, Co-Fund III.

£3 million investment in Coleraine companies will improve outcomes for cancer and metabolic disease patients | Manufacturing & Supply Chain

Invest Northern Ireland has announced that two Coleraine SMEs are the first to receive investment from its £39 million equity fund, Co-Fund III. StimOxyGen and Dia Beta Labs, two life & health science spin-out companies from Ulster University, have each raised £1.5 million of public and private funding to assist with their growth plans. These investment rounds have been directly supported and leveraged by Co-Fund III, one of three funds that mak…

£3million investment in Coleraine companies will improve outcomes for cancer and metabolic disease patients

£3million investment in Coleraine companies will improve outcomes for cancer and metabolic disease patients 25 June, 2025 Pictured L-R are Steven Scullion, Director of Corporate Finance, Invest NI; Prof Peter Simmons, Chair of Dia Beta Labs; Dr Sian Farrell, Chief Executive of StimOxyGen; Stuart Gaffikin, Senior Investment Manager, Clarendon Fund Managers.Invest Northern Ireland has announced that two Coleraine SMEs are the first to receiv…